Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
作者信息
Freedland Stephen J, Gleave Martin, De Giorgi Ugo, Rannikko Antti, Pieczonka Christopher M, Tutrone Ronald F, Venugopal Balaji, Woo Henry H, Ramirez-Backhaus Miguel, Tarazi Jamal, Tang Yiyun, Ganguli Arijit, Haas Gabriel P, Shore Neal D
机构信息
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California.
Section of Urology, Durham VA Medical Center, Durham, North Carolina.
出版信息
Future Oncol. 2025 Feb;21(5):501-514. doi: 10.1080/14796694.2024.2426425. Epub 2024 Dec 12.
Abstract
摘要
相似文献
1
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?简明摘要：恩杂鲁胺联合或不联合亮丙瑞林治疗对高危生化复发患者的预后及生活质量有何影响？
Future Oncol. 2025 Feb;21(5):501-514. doi: 10.1080/14796694.2024.2426425. Epub 2024 Dec 12.
2
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.一项局部治疗后 PSA 升高的高危非转移性激素敏感性前列腺癌中恩扎卢胺联合亮丙瑞林和恩扎卢胺单药治疗的 3 期随机研究：EMBARK 研究设计。
BMJ Open. 2021 Aug 12;11(8):e046588. doi: 10.1136/bmjopen-2020-046588.
3
Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?简明摘要：前列腺特异抗原倍增时间是否会影响非转移性去势抵抗性前列腺癌患者的生存时间及其医疗成本？
Future Oncol. 2023 Oct;19(31):2075-2082. doi: 10.2217/fon-2023-0354. Epub 2023 Aug 30.
4
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.LBA02-09：EMBARK 研究：恩扎卢胺或安慰剂联合醋酸亮丙瑞林与恩扎卢胺单药治疗高危生化复发前列腺癌的 3 期随机研究。
J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2.
5
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.TALAPRO-2 研究结果的简明报告：他拉唑帕尼联合恩扎卢胺对比安慰剂联合恩扎卢胺用于晚期前列腺癌患者。
Future Oncol. 2024;20(29):2123-2135. doi: 10.1080/14796694.2024.2362108. Epub 2024 Jul 12.
6
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?通俗易懂的总结：当晚期前列腺癌患者接受恩杂鲁胺治疗时，前列腺特异性抗原水平的下降能否表明其生存期？
Future Oncol. 2023 Sep;19(29):1953-1960. doi: 10.2217/fon-2023-0135. Epub 2023 Aug 10.
7
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗前列腺癌生化复发的生活质量研究
NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22.
8
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
9
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.他拉唑帕尼联合恩杂鲁胺对比安慰剂联合恩杂鲁胺用于晚期前列腺癌患者及特定DNA修复基因的变化：TALAPRO-2研究结果的通俗易懂总结
Future Oncol. 2025 Mar;21(6):637-652. doi: 10.1080/14796694.2025.2449754. Epub 2025 Jan 30.
10
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.单独使用恩扎卢胺和联合免疫疗法治疗非转移性去势敏感性前列腺癌的临床和免疫影响。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001556.
Zotero 插件